Overview

Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with FOLFOX 4 Chemotherapy or Panitumumab with FOLFIRI Chemotherapy in Subjects with Wild- Type KRAS Colorectal Cancer and liver-only Metastases.

Phase:

Phase 2

Details

Lead Sponsor:

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Collaborator:

Amgen

Treatments:

Antibodies, Monoclonal
Panitumumab